Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05671159
Active, not recruiting Not applicable

COMPArative Study of the Consequence on innaTe Immune Response du to Bacterial or Viral Infection in Patients Admitted to Intensive Care Unit

NCT05671159 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Limoges
Phase
Not applicable
Started
2023-02-19
Last updated
2026-06-26

Condition(s) studied

Viral InfectionSepsis

Investigational drug(s) / intervention(s)

Blood sample

Blood sample: A supplementary blood sample will be taken including a 5mL EDTA tube and a paxgene tube

Study summary

Patient admitted in intensive care unit (ICU) for acute infection whether it be viral or bacterial had major impairment of the immune response. One hallmark of the immune impairment is presence of immature granulocyte (IG) in blood. Depend of initial trigger (virus or bacteria) concentration, phenotype and function of IG seems to be different. In this prospective trial, immature granulocytes will be analyzed in depth in immunocompetent patients hospitalized in the intensive care unit for an acute viral or bacterial infection.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Bacterial infection: * Adult patient hospitalized for less than 24 hours in ICU for community documented sepsis * Vasopressor support * SOFA score \> 4 * Viral infection: * Adult patient hospitalized for less than 24 hours in ICU for confirmed viral acute infection. * High flow oxygen, non-invasive or invasive ventilation since less than 24 hours * Moderate to severe ARDS with PaO2/FiO2 \< 200mmHg and a FiO2 ≥ 0.6. Exclusion Criteria: * Bacterial infection: * Antibiotics or hospitalized in ICU in the previous 3 months * Immunocompromized patient * Ongoing acute or chronic viral infection * Viral infection: * Antibiotics or hospitalized in ICU in the previous 3 months * Immunocompromized patient * Current antibiotics * Ongoing chronic viral infection.

Primary outcome measure(s)

  • Granules expressing CD123 and CD64 — Day 0
    Measurement by flow cytometry of the percentage of granules expressing CD123 and CD64 depending on the type of infection (viral or bacterial).

Trial sites (1)

FacilityCityRegionStatus
Limoges University Hospital Limoges France

More University Hospital, Limoges trials in France

Pulmonary Function in Patients Recovering From COVID19 Infection : a Pilot Study Active, not recruiting
Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes Recruiting
Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures "Outside the Walls" by Dual Screening Method RTDs and FibroScan® Recruiting
Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures Recruiting
Tolerance Study of Robotic-Assisted Virtual Reality Walking Rehabilitation for Non-Walking Stroke Patients Recruiting

Other trials for the same condition

Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate in Sepsis-Associated Acute Kidney Injury Recruiting
Evaluation of Diagnostic Accuracy and Clinical Performance of the UIICORE BSI Test Recruiting
Evaluation of the Dialytic Clearance of the Combination of Peracillin and Tazobactam Starting soon
Early Optimization of Ceftazidime Regimen in Critical Care Starting soon
Hemodynamic Evaluation Using Microcirculation for Early Treatment of Septic Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05671159 on ClinicalTrials.gov ↗ ← All trials in France